Open Trials at PCC

Available Clinical Trials at Pacific Cancer Care

Pacific Cancer Care is driven by a vision to be the leader for the treatment of cancer in the Monterey County. Our clinicians and investigators identify and conduct Phase I-IV treatment options that are new and innovative, and that will positively impact our patients. Below is a list of clinical trials currently available at Pacific Cancer Care.

For more information regarding clinical trial opportunities, please contact us at (831) 375-4105.

Solid Tumor and Hematologic Malignancies

Protocol Number: Patient-centered Outcomes Research Institute Study – Stanford – 63775

Protocol Title: Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults with Cancer

More Information available at: https://clinicaltrials.gov/ct2/show/NCT05297734

Breast Cancer

Protocol Number: CELC-G-301

Protocol Title: Phase 3, Open-Label, Randomized, Study Comparing Gedatolisib Combined With Fulvestrant & With or Without Palbociclib to Standard-of-Care Therapies in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Previously Treated With a CDK4/6 Inhibitor in Combination w/Non-Steroidal Aromatase Inhibitor Therapy

More information available at: https://clinicaltrials.gov/ct2/show/NCT05501886

Protocol Number: EMBER-4

Protocol Title: EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence

More information available at: https://clinicaltrials.gov/ct2/show/NCT05514054

Urothelial Cancer

Protocol Number: SGNDV-001

An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2 (IHC 1+ and Greater)

More information available at: https://classic.clinicaltrials.gov/ct2/show/NCT04879329

Hematologic Malignancies

Protocol Number: MK-4280-003

Protocol Title: A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies

More information available at: https://clinicaltrials.gov/ct2/show/NCT03598608

 

Through partnerships with organizations such as the Dana Farber Cancer Institute and Parker Institute for Cancer Immunotherapy, our patients rest assured knowing that a full complement of research and clinical resources are available to them, all synchronized and supervised by their Pacific Cancer Care team.